# Genflow Biosciences’ Dr Eric Leire highlights funding, pipeline progress and near-term catalysts

- Link: https://www.directorstalkinterviews.com/genflow-biosciences-dr-eric-leire-highlights-funding-pipeline-progress-and-near-term-catalysts/4121249777
- Published: 2026-04-22T13:18:21+01:00
- Author: Amilia Stone

**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF) Chief Executive Officer Dr. Eric Leire caught up with DirectorsTalk to
discuss recent progress, funding, market opportunities, and upcoming catalysts.

**Q1: Some incredible progress and achievements made over the last 6 to 12 months.
Eric, what were the key highlights for you?**

**A1:** I would especially like to focus on the dog study, animal health, where 
the ongoing clinical trial is moving according to the plan, with now the recent 
publication of interim results that were very promising.

Second, we moved to an ophthalmic programme with the ambition to change the way 
we treat glaucoma. Glaucoma now is treated as a pathology of the high pressure in
the eye, but the real problem is the degeneration of the retina, so your posterior
part of the eye and the beginning of the nerve. We have here some preliminary data
that are extremely exciting. We can revolutionise the way we treat glaucoma.

I will not forget that we got some good progress in sarcopenia, and also, we are
moving very comfortably with the transition from AAVs to now an mRNA LNP platform.

It’s all very positive.

**Q2: You recently announced successful funding and a €4 million grant. What will
that funding be used for?**

**A2:** That’s part of the excitement for 2025. It was a successful year. We secured
the MASH grant that will cover €4 million, so that’s a significant addition in terms
of non-dilutive grants. It’s coming in addition to the grant we have for the sarcopenia
programme and for the ‘Exofastrack’ programme. So, we have now three grants that
are funding the company.

In addition to that, we did also a nice series of little fundraising, classical 
fundraising, non-dilutive with historical shareholders.

**Q3: What can you tell me about the size of the markets that you were targeting?**

**A3: **That’s one part of the company that we don’t communicate enough.

One of the appeals of Genflow Biosciences is the fact that we’re targeting very 
large market opportunities. When I say large market opportunities, I’m not talking
only about the number of patients we could treat, but also the size of the unmet
need that allow us to have some very attractive pricing opportunity.

For MASH – Metabolic Dysfunction-Associated Steatohepatitis – for example, we target
a segment of the market. The early stage of MASH is relatively well covered with
GLP-1 and a product from Madrigal, Resmetirom. We are more interested in the late
stage when the MASH has really evolved towards cirrhosis and risk of hepatocarcinoma.
Here, we only compete against liver transplantation. Very expensive, very difficult,
a lot of logistical problems. So, very nice competitor to compete with. It’s still
a very large market opportunity. This segment is one third of MASH, MASH being more
than 30 to 40 million people based on different estimations in the world.

If I take glaucoma, the second cause of blindness, treated only to lower the pressure
into the vitreum, we will change that as an opportunity also to prevent the evolution
toward blindness. As you imagine, that’s a huge opportunity.

Sarcopenia also is a therapeutic area with a large unmet need and a very large number
of patients. So, yes, we are not targeting small markets. The market opportunities
are extremely large for the company and that’s definitely one of the appeals for
the investor regarding Genflow Biosciences.

**Q4: Just turning to the future now. What can investors be looking out for in terms
of news flow?**

**A4: **Short term, we will publish the final results of the animal health, the 
dog clinical trial we’re running and we’re starting now to discuss with animal health
companies, two are under CDAs. We want to sell this programme or to out license 
this programme to find a partnership, a partner in an animal health company. We 
definitely have no added value in animal health in terms of commercialisation and
development of product. Animal health partner will do much better than us.

This will provide certainly very nice non-dilutive revenues from business development
within the company and should have a major impact on our market cap. For example,
let’s say the worst scenario, we have an upfront. The upfront is way larger than
market cap, you can imagine the impact on our market, on our share price in relatively
short term. So, very nice opportunity.

Other than that, we have also the opportunity to have partnerships and we will publish
results in glaucoma, and we expect to present at the conference American Academy
of Ophthalmology in the US in New Orleans at the end of the year.

Last but very important, maybe less important for the investors, but extremely important
for us and for the business development, is IP. Our key patent is now entering national
phase, and we have some geographies where we are extremely close to having the patent
granted. So, when we have a patent granted, that is very nice protection for the
company, it changes also the valuation of the company, and it allows you to have
access to the business development opportunities.

Share on: